Valneva SE

Good day and thank you for standing by. Welcome to the Villeneuve's First Quarter 2025 Financial Results Conference call. At this time all participants are in listen only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during the session, you will need to press star one one on your telephone keypad. You will then hear an automated message advising your hand is raised. To withdraw a question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Joshua Drum, as the president of Global Invest Relations. Please go ahead.

Thank you. Hello and thank you for joining us to discuss Villeneuve's First Quarter 2025 Results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the three months ended March 31st, 2025, which were published earlier today, available within the financial reports section of our investor website. I'm joined today by Villeneuve's CEO, Thomas Lengelbach and CFO, Peter Bueller, who will provide an overview and update on our business, as well as our key financial results for Q1 2025. There will be an analyst Q&A session at the conclusion of the prepared remarks. Before we begin, I'd like to remind listeners that during this presentation, we will be making forward-looking statements, which are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by these forward-looking statements. You can find additional information about these risks and uncertainties in our periodic filings with the Securities and Exchange Commission and with the French Market Authority, which are listed on our company website. Please note that today's presentation includes information provided as of today, May 7th, 2025, and Villeneuve undertakes no obligation to revise or update forward-looking statements, except as required by applicable securities laws. With that, it's my pleasure to introduce Thomas to begin today's presentation.

Thank you, Josh, and good day to all of you. Pleasure to provide the update during today's earnings call. Yeah, the first quarter, 2025, was a solid quarter with strong overall financial performance. Total revenue reached almost 50 million euros. The reduction in operating cash burn is reflecting our continuous focus on cash and cash management. And this is also shown in a cash position north of 150 million euros, excluding the recent proceeds from our April ATM transaction. And in quarter one, we also made progress on the regulatory front, predominantly around ICCC, label extensions, and further approvals. When we look a little bit more into the details of the first quarter, 2025, we got a new ICCCRO contract awarded by the US Department of Defense. We responded to the French government's call for ICCC to combat the chikungunya outbreaks in La Réunion and Mayotte. And we responded to the cholera outbreak in Mayotte by supplying doses of Ducoral, so all in line with our mission to address unmet medical needs. With regards to the key regulatory achievements that I mentioned earlier, we got the marketing authorization for ICCC in the UK in individuals 18 years of age and older. And we also submitted the respective adolescent label extension application. We got the ICCC label extension in Europe for individuals 12 years of age and older by the European Medicines Agency. And the ICCC marketing authorization in Brazil represents the first approval of a chikungunya vaccine in an endemic country. On clinical data and pipeline progress, we reported high sustained immune response in adolescents one year after X-Chick vaccination with a single dose and as part of our phase three. We reported positive phase two pediatric results for X-Chick and as such could decide the dose for the planned phase three study in the pediatric population. And we initiated the first vaccination in the phase two infant study in Africa of our tetravalent shigella vaccine candidate S4V2. Turning our attention a little bit to Lyme, you all are very aware of the Lyme program and the medical needs that Lyme disease represents globally. There is no vaccine available to prevent Lyme disease in humans. And we see a growing annual burden of disease with almost half a million cases reported and this are confirmed cases reported in the United States. More than 100,000 cases reported in Europe and those numbers are heavily impacted by under reporting or not even existing reporting systems in some of the countries. When we look at the clinical manifestations, two to 30% develop really severe clinical manifestations including caditis, neuroporiosis or arthritis and five to 10% have persistent symptoms even following treatment. Therefore, we see a huge unmet medical need preventative solution, enhanced commercial opportunity for Vaneva especially given that we are talking about almost 90 million people in the US and more than 200 million people in Europe who live in endemic regions where Lyme represents a major risk. You all know that we are in year three or in the third tick season of the ongoing phase three study Valor and we are expecting first data at the end of this year. This is a study that includes more than 9,000 participants five years of age and above who are at high risk of Lyme disease. We are measuring here against the placebo control setting randomized one to one against placebo two to one North America, Europe and the primary endpoint is the rate of confirmed Lyme disease cases. So prevention of the disease after the second consecutive tick season and right now we have the second cohort undergoing the booster vaccination and then we have quite significant number of secondary endpoints including the rate of confirmed Lyme disease cases after the first season after the primary series. So very exciting year and we hope to see the first data set by the end of the year which will be followed by a significant number of secondary endpoints and other data associated with the study and provided positive data we expect filing with the regulatory authorities next year. With that let me turn over to Ikshik. You know that our Chikungunya vaccine is a highly differentiated vaccine and we are glad that we have been able to report strong clinical data thus far across all the studies and across all the target populations that we have been evaluating and got licensed by now. At the same time we have experienced recent changes to Ikshik recommendations in response to reports of serious adverse events in frail elderly individuals. As such ACIP recommended precaution for use in 65 plus, EMAR cautioned against use in frail older adults especially those with comorbidities and in France a Spanish recommendation for use in 65 plus. All of that you know pending ongoing investigations. As we stated in our different publications and communications we are highly committed to standards of safety and appreciate therefore these precautionary decisions. All investigations into SAEs remain ongoing and it's worth noting that causality has not been definitely established at this point in time. We will of course continue to closely monitor all reported adverse events and cooperate fully with health authorities while working proactively on a potential update of the product invitation. We have now a bit more than 40,000 doses administered. So doses of Ikshik that landed in people's arms and we continue to see a positive risk benefit in the vast majority of people with potential exposure to the disease. And we would like to remind one more time that Ikshik must not be given to people who are immunodeficient or immunosuppressed due to disease or treatment. When we look at the further development of Ikshik that we are currently conducting, we are preparing for the post-parketing effectiveness phase four program. This is a program to confirm the effectiveness following licensure based on an immunological and disorogative protection, the so-called accelerated approval pathway and to further help optimizing description of the safety profile. We are planning an observational effectiveness study in Brazil, pragmatic randomized control effectiveness and safety study in endemic countries and prospective safety court study and pregnancy surveillance in Brazil. We have ongoing label extensions to expand access to the vaccine for all age groups. And we reported already the data, phase three data in adolescents, which landed in some countries and some regulatory jurisdictions already in a label extension. Others are still under review. And we plan to start a phase three study in children aged one to 11 years of age. On the product profile, all of that and across all programs, we would like to confirm the long-term durability of the immune response to further differentiate our vaccine. Turning to Shigella, which is really the most advanced program right now in the tetravalent bioconjugate vaccine space targeting shigulosis infections. It's a program that we have partnered with Lima Tech. It includes the four most common pathogenic Shigella bacteriocereotypes. Lima Tech in the past reported positive phase one to clinical data and the program got awarded FDA fast-track designation. We expect a huge un-mathematical need, of course, primarily in children living in low-medium income countries, but also a substantial added value for travelers and military personnel. And the Shigella disease and the work around Shigella vaccines has been identified as a priority by the World Health Organization. As mentioned at the beginning, we launched a phase two infant study this year and we expect data already for a later part of this year. We have an ongoing phase two B, so-called controlled human infection models. This is a study that goes in two steps. The first step is to optimize dose and schedule. Second is to challenge and get with the challenge a first idea around pilot efficacy. We announced that we have slightly extended the immunogenicity phase, so the so-called step one. And as such, we are not expecting the pilot efficacy data as previously announced in the second half of this year, but in the first half of next year. And of course, we will work continuously on this exciting program and make sure that we progress towards the next development phases. Turning to Zika, we expect phase one results later this year on our second generation optimized vaccine candidate against the Zika virus. It's an inactivated whole virus vaccine based vaccine that leverages our technology that we developed and further optimize as part of our COVID work and our COVID vaccine during the pandemic, VLA 2001. And of course, we hope to see positive data that would enable further development against the disease that can have quite devastating effects. And please be reminded that there is currently absolutely no vaccine of specific treatment available. And as such, we hope also for support of public institutions, for example, to help advance a potential vaccine against Zika virus. With that, I would like to hand over to Peter to provide us with the financial report.

Thank you, Thomas. And good morning and good afternoon to all of you. Now let's look at the financial report for the first quarter of fiscal year 2025. Product sales reached 48.6 million euros and increased by .2% versus the first quarter of the prior year. The Chiara sales reached 27.5 million euros, .5% above last year. And the year over year growth is driven by a strong increase in sales to US military, but also into the travel channels. In addition, the first quarter includes higher sales related to stock replenishment in indirect markets. As you may recall, the first quarter of 2024 had been adversely impacted by supply constraints. Du Corral sales grew by .4% and reached 12.3 million euros. The increase in Du Corral sales is primarily driven by a shipment of 1.1 million euros to the French island, My Yacht. X-Chic sales reached 3 million euros in the first quarter of 2025, compared to 200,000 euros in the first quarter of last year. X-Chic was first launched in the United States in quarter one of 2024. And the increase in sales is related to the continuous ramp up of sales in the United States and the launch in additional territories, mainly in France and Canada. In the first quarter of 2025, we received an order for 40,000 doses of X-Chic to respond to the Chicungunya outbreak on La Réunion. The significant majority of these doses were shipped early April, and hence sales will be recorded in the second quarter. Third party products increased by 41% to 5.8 million euros, compared to 4.1 million euros in the first quarter of last year. As mentioned previously, we expect third party product sales to decrease over time, and this year over year increase for Q1 is primarily due to supply constraints faced by our third party partners in Q1 of last year. Over time, we expect the continued reduction of our third party business to have a positive impact on the company's gross margin. Foreign currency effects have no material impact on the year over year sales performance. I'm moving on to the income statement. Total revenues reached 49.2 million euros versus 32.8 million euros in the first three months of 2024. Cost of goods and services increased marginally versus prior year, despite the significant increase in sales. Gross margin on commercial products, excluding X-Chic, amounted to 62.7%, compared to .9% in the first quarter of 2024. The significant improvement in gross margin is primarily due to better manufacturing performance, with fewer batch failures and inventory adjustments. X-Yaris gross margin reached 72.6%, which is significantly better than the 52% of last year, and even exceeds pre-COVID levels. Duqaraz gross margin reached 52.2%, compared to 40%, to below 40% in the first quarter of last year. Research and development expense increased by around two million euros to 15 million euros driven by costs related to our new Shigella program, following the start of our collaboration with Limatech Biologics in the fourth quarter of last year. Marketing and distribution expense in the first quarter reached 10.4 million euros, compared to 11.3 million euros in the prior year. The decrease is mainly related to lower advertising and promotion expense. General and administrative costs were reduced to nine million euros, compared to 11.7 million in the prior year. The decrease is related to a lower spend on recruiting, lower insurance costs, and savings in professional services. The operating loss of the first quarter 2025 is reported as minus six million euros, compared to an operating profit of 68.2 million euros in the first quarter of the prior year. The first quarter of 2024, we sold the priority review voucher, obtained upon approval of the X-Chicungoonia vaccine, X-Chic, in the United States. This resulted in a non-recurring revenue of 90.8 million euros. Net finance and income tax expense is reported at 3.3 million euros, compared to 9.3 million euros in the prior year. The lower expense is mainly related to a foreign exchange gain of 3.7 million euros, due to the development of the US dollar versus euro exchange rate, and the related balance sheet revaluation. With this, the loss for the first quarter of fiscal 2025 reached 9.2 million euros, compared to a profit of 58.9 million euros in the prior year. EBITDA is slightly negative, while last year was positive, driven by the sale of the priority review voucher. Before we move to the guidance, a word on cash. As mentioned by Thomas at the beginning of the call, total cash and cash equivalents at the end of March were 153 million euros, compared to 168 million euros at the end of prior fiscal year. In the first quarter of 2025, we significantly reduced the cash used in operations, compared to the prior year from 28.4 million euros to 8.1 million euros, mainly driven by higher sales and good cost control. In addition, as mentioned at the beginning of the call, and as stated in our press series, in April, we issued new shares for a value of 14.2 million euros through our Add to the Market program, based on a reverse inquiry from Novo Holdings. Through this transaction, plus additional shares acquired in the open market, Novo is now one of our top shareholders. Now moving to slide 22, to review our guidance for fiscal year 2025. The guidance has unchanged compared to the full year 2024 earnings call. We reiterate our product sales guidance of 170 to 180 million euros for the fiscal year, and total revenues of 180 to 190 million euros. Total R&D expense are expected between 90 and 100 million euros, partially offset by grant funding and R&D tax credits. As demonstrated in the first quarter, we are on track to reduce our operational cash burn by 50% on a full year basis, with the goal of being able to reach key inflection points with our existing cash. In the midterm, we continue to focus on gross margin, and we see a path to potential sustained profitability from 2027 based on a successful Lyme disease vaccine approval and commercialization. This concludes the finance section of this call, and I would like to hand back to Thomas to discuss our major growth drivers. Thank you so

much, Peter, for this comprehensive financial report. Turning to page 24 of the presentation, looking a little bit into our expected growth drivers for 2025 and beyond. Of course, it's all about Lyme for the time being, and therefore, we are very much looking forward to the results of VLA 15, and hopefully its success, which, as Peter pointed out, has the potential for sustained profitability upon approval and commercialization, of course, driven by the substantial milestones and royalties kicking in towards the latter part of 2027, according to current timelines and expectations. When we look at the commercial business, we have shown that we have been able to optimize and grow our commercial business, and we expect, in the near term, continued growth for both of the existing older brands, like Xero and DucaRan, but also expect Xjig to gain further global traction. When we look at the future pipelines, we expect really value creation through new pipeline programs and ongoing programs that we have already in the pipeline, including Shigella and Zika, and our goal, as communicated previously, is to have a next phase three program ready post-successful introduction of the Lyme vaccine. And with that, we see overall a really good prospect of our business, with, of course, major growth drivers around Lyme, but also major growth expected from our commercial business and upside from future or existing clinical and preclinical R&D assets. With that, we would like to conclude our presentation and hand back to the operator to take your questions.

Thank you, dear participants. As a reminder, if you wish to ask a question, please press star, one, one, on your telephone keypad and wait for your name to be announced. To withdraw a question, please press star, one, one, again. Please stand by, we'll compile the Q&A rules, so this will take a few moments. And now we're going to take our first question. And it comes to the line of Mario Raycroft from Jeffreys. Your line is open, please ask your question.

Hi, congrats on the progress, and thanks for taking my questions. I'll ask a quick one on Ixtric first and then one on Lyme. I guess for Ixtric, just wondering, what are next steps regarding the label? Wondering if you've heard back from FDA regarding the label extension application for adolescents. That was submitted a couple months ago. And then what are next steps regarding potential need to add a language release baby?

Yeah, thanks for your question, Marie. So I start with the last one first. The review with the FDA is still ongoing. So we have submitted, as you rightly pointed out, and we are waiting for their reply and hopefully soon the adoption of the label to include the 12 and above. Yeah, the current situation and next steps. At this stage, we have seen changes to the recommendation. You know that we are absolutely committed to the highest standards of safety. So the investigations are ongoing. We know that all of that has occurred in frail older individuals. We have strongly recommended and continue to do so that healthcare providers supply individualized clinical judgment when determining the proptiveness of Ixtric for elderly frail patients. And we are supporting the regulatory authorities as much as we can on evaluating those cases. And we'll review also whether certain additional precautions or contraindications in specific population groups may be warranted.

Got it, okay, that makes sense. And then for the phase three LIME study, can you remind me what the p-value threshold is for the primary endpoint of confirmed LIME cases? And when considering GMT from historical studies, how are you setting expectations for the bar and what antibody titer you will need to achieve to get sufficient protection?

So unfortunately, I can't disclose the p-value for the phase three study, but it is sufficiently powered. According to the expectations and according to the, what's the epi studies and disease burden evaluations, which most of them got published by Pfizer. And I think that's basically what we can say. I would like to point your attention to a publication, a joint publication that we also referenced by Pfizer and Valneva where, I would say, a potential protective immunological threshold has been hypothesized, I would say. I think we discussed in length in the past, Murray, that it is very difficult at this point in time. There has never been an immunological correlate for LIME. And of course, essays are very different. I mean, and we can, of course, send you again the link to the respective publication.

Okay,

yeah,

that sounds good and that would be helpful. Okay, thanks for taking my questions. I'll hop back in the queue.

Thank you. Now we're going to take our next question. And it comes from Rajan Sharma from Goldman Sachs. Your line is open, please ask your question.

Hi, thanks for taking my question. So just one on LIME actually. So I think you'd do $143 million in milestones from Pfizer as an initial milestone. I was wondering, would part of that be due with a potential positive phase three or is that related specifically to approvals, whether that's in the US or elsewhere? And then secondly, I was just wondering if you could just comment on tariffs, which is obviously a focus in the sector at the minute. Be helpful just to get your perspectives on potential impact for Valneva because it just helps understand your manufacturing footprint and any potential mitigations you may have. Thank you.

Yeah, hey Rajan, it's Peter. Thanks for the question. So yes, you're absolutely right. There is a milestone of $143 million that Pfizer would pay as upon first commercialization. So it's not at the end of phase three. There are basically three triggers for that are three parts of the $143 million. There is a first commercial phase in the US, first commercial phase in Europe and ACIP opinion. And all three events are supposed to happen in 2027, basically. On tariffs, and just to add maybe that there's another, there will be another 100 million commercial milestones afterwards based on sales thresholds, cumulative sales thresholds and royalty rates of between 14 and 22%, just to remind everybody. On tariffs, it's obviously something we're closely following. I think right now it's difficult to express an opinion on it because nothing has been defined in terms of tariffs. So too many unknowns. We are of course looking at potential mitigation strategy or initiatives to your question on our manufacturing footprint. So our vaccines are basically all manufactured in Europe. So drug substance for XeroDixtric is manufactured in Scotland. And then field finishing happens in Germany. And as far as Tukor is concerned, it's all produced in Sweden

and

the IP is also in

Europe. Okay, thank you. Thank you.

Now we're going to take our next question. And it comes to land of Amil's Divan from Guggenheim Securities. Your line is open, please ask your question.

Great, thanks for taking my questions. Maybe a couple on the financial side. So one, the sales this quarter are quite a bit higher than consensus. You know, to maintain your full year guidance. So I'm just trying to get a sense of the nuances there maybe relative to what you see from consensus estimates right now. I mean, just one in terms of sequencing of the DOD sales that drove through the first quarter for Xero, maybe is that a reason to not be too optimistic on that read through the rest of the year? Or is there maybe some extra sort of services built in given some of the label updates that are coming on that front? And then the second question is just more on the gross margin side. And you've talked about, kind of getting back to these pre-pandemic levels. I think extric are one of the key drivers there. Just if there was a shift in sort of uptake of that, that vaccine given some of the new label updates and safety questions, would you still feel comfortable getting to the pre-pandemic levels on gross margins? Even again, if your product maybe shifts a little

bit. Yeah, thanks for the question. So starting with sales, yes, absolutely our first quarter revenues are above the consensus. I think it was expected by us, and as I said in the call, so we did see strong growth in particular in Xero on both travel and also DOD. But as I mentioned, last year was very heavily impacted by restricted supply. That was resolved in April of last year. So you will see this year slightly different phasing, which is also why we do not see right now any change to our guidance. So first quarter for us was in line with what we had anticipated. As you know, on sales to the Department of Defense, so we have not published the number, but as you saw, we signed a new contract, and we supplied ongoing according to plan, and it has also increased versus prior year. In terms of gross margin, we said in the past that we expect X-Chick over time to yield a better gross margin than the other products. I think that we're still considering this, of course. This has not changed. I think overall Q1 gross margin was very good. And you're right, we did say in the past, we expect to reach a pre-pandemic level, although we have not defined this for 2025, we have not added on gross margin for 2025. But of course,

we're very pleased to see where we were in Q1.

Okay, thank you.

Thank you. Now we're going to take our next question. And it comes to the line of Samir Devani from IX Securities. Your line is open, please ask your question.

Hi, guys, thanks for taking my questions and congrats on a good quarter. Have you now fulfilled the MyONAT order in this quarter?

The MyONAT

order?

Not the

MyONAT, the MyONAT order. Or the MyOT?

MyOT, yeah, so that was the two corral. Yes, that was actually fulfilled in the first quarter.

Okay, fine. And then just on the MyONAT order, can you help us in terms of thinking how we should phase this in terms of our modeling for X-Chick? Is it going to lead to a reasonable spike in the next quarter and then a sort of fall away in Q3?

Yeah, so as we said, we supplied a small number of doses at the end of Q1 and the remaining part will be supplied in Q2.

Or it was already supplied in Q2, I should say.

Mm-hmm.

Okay, and then finally, just on the mechanism for X-Chick and it being alive, attenuated. I'm just wondering, Thomas, if you could comment on, has this made you reconsider the sort of dose that you might use in the pediatric studies in light of the potential adverse events you're seeing in the elderly?

Mm-hmm, it's of course a good question. So we don't see, at this point in time, any unexpected safety profile in younger adults or even adolescents. So at this point in time, we have not reconsidered those for the phase three infant study that we had previously announced. But as I said, at this point in time. So that's all I can say for now.

Okay, that's great, thanks very much.

Thank you. Now we'll proceed with our next question. And the question comes from the line of Suzanne Vanverhoizen from Van Laatschot Kampen. Your line is open, please ask a question.

Hello, this is Samuel Lanthor, Suzanne. Thank you for taking our questions. For the LIME phase three program and the last tick season now starting, can you provide some color on the infection rate so far in this study? And is this monitored and in line with the company's expectations? And secondly, with the study consisting of two sequential cohorts of subjects, is the first cohort receiving a second booster this season already? And will you report data on this too at the year end readout? And then lastly, regarding the latest news that came from vaccine policy makers, could you comment which elements may or may not affect your vaccine business? And do you see particular risks or opportunities there?

So many questions, so thank you for that. So I would say we have not, yes, we are, of course, monitoring on an ongoing basis the overall LIME cases during the study. We are and will not comment on those other than we have seen the overall profile over the past couple of years being pretty consistent in terms of number of LIME cases and we see at this point in time no concerns. With regards to the study cohort, the answer is no. With regards to the other activities that you were mentioning, namely impact on the business, I mean, at this point in time, probably no one is able to really say what all this political dynamics in the United States mean with regards to any of the vaccines on the market or in development and I think we should probably not speculate about that. And will it have an impact? Probably yes, probably not. So I think we have to wait until certain things become more defined and turn into real requirements

or policies. Excuse me, any further questions?

Thank you very much.

Thank you. Now we're going to take our next question. And it comes from Oscar Hafenlam from Brian Garnier and Co. Your line is open, please ask your question.

Hi, thank you for taking my questions. So the first one on Xero, relative to Q4 last year, sales growth is similar. So we're just wondering if there were any seasonality effects seen during this first quarter and then maybe how you forecast

the growth of the asset for the remaining of the year. So on Xero,

like I said, the impact is more quarter over quarter. I don't think there is any particular seasonality impact in Q1, except as I mentioned also, particularly in one of our indirect markets, there's probably some stocking effect, but in the overall picture, I will not say it's absolutely material. And I'm sorry, I didn't get the second question. Can you maybe repeat that one?

Yeah, just how do you forecast the growth of Xero for the remaining of the year?

Oh, yeah. So we have not guided specifically on Xero, but what we did say is we expect Xero to continue to grow double-digit CAGR, which we would expect for this year's double-digit growth. But we have not guided specifically

on the number for Xero.

Okay, thanks. And maybe quickly a second question this time on X-JIC. I was wondering if following the updated recommendation from the French HAS, there could be a potential impact related to the order book of vaccines

that were ordered for the outbreak in La Réunion. We have at this point in time, confirmed the 40,000 doses order, and we delivered the 40,000 dose order and all the rest we have

to see. Okay, thank you. Thank you. Dear

participants, as a reminder, if you wish to ask a question, please press star 1-1 on your telephone keypad. Yes, give us a moment. And the question comes to the line of Simon Scholes from First Berlin. Your line is open. Please ask a question.

Yes, good afternoon. Thanks for taking my questions. I've got three. First of all, I was wondering if you could give us some color on the idle capacity costs and your efforts to reduce these. Then secondly, on the Xero gross margin, which was 73% in Q1, I mean, do you think the gross margin on Xero is sustainable at this level? And on the Ducarral gross margin, do you expect that to be able to get that close to the 60% over time? Thanks.

Yeah, so let me start with the gross margin questions. So on Xero, we do think that Q1 was probably not representative where it will be for the full year. We do expect an improvement, of course, versus prior year, but I think north of 70%, I think it's probably not what we will see for the full year. I think on the Ducarral, we haven't guided on the gross margin, but I think the Q1 gross margin is probably roughly representative. On the idle cost, so for the first quarter, I would say it was probably roughly around 2 million euros. So this is primarily related, of course, one, because we have large capacity, but also because some of the, especially the new manufacturing sites in Scotland, we are in progress of transferring over production. So over time, we will see a reduction that idle cost, of course.

Okay, thanks very much.

Thank you. Now we're going to take our next question. Just give us

a moment. My apologies. I'm sorry. Yes, please stand by. Excuse me, I

know that you would like to ask a question. If you don't mind, please, can you press star one one again?

Dear speakers, I'm going to ask the questions

for today.

I

would now like to hand the conference over to the management team for any closing remarks.

Thank you so much for your attention today. Good questions, and as usual, and your interest in following the company closely, and we are looking forward to staying closely in touch while we are focusing on our exit. The execution this year, the best strategic value for the future. Thank you so much.

This concludes today's conference call. Thank you for participating. You now may all disconnect. Have a nice day.